Clearmind Medicine Inc.
Clearmind Medicine Inc. (CMND.CN) Financial Performance & Income Statement Overview
Review Clearmind Medicine Inc. (CMND.CN) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Clearmind Medicine Inc. (CMND.CN) Income Statement & Financial Overview
Explore comprehensive income reports for Clearmind Medicine Inc. CMND.CN, broken down by year and quarter.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $11512.00 | $15191.00 | $0.00 | $0.00 |
| Gross Profit | -$11512.00 | -$15191.00 | $0.00 | $0.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $483730.00 | $343122.00 | $322956.00 | $227478.00 |
| SG&A Expenses | $1.09M | $1.13M | $980549.00 | $1.16M |
| Operating Expenses | $1.57M | $1.46M | $1.30M | $1.38M |
| Total Costs & Expenses | -$1.59M | $1.47M | $1.30M | $1.38M |
| Interest Income | $91669.00 | $85024.00 | $33955.00 | $60576.00 |
| Interest Expense | $36160.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $11512.00 | $15191.00 | $15738.00 | $8631.00 |
| EBITDA | -$1.18M | -$1.46M | -$1.69M | -$1.53M |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -$1.59M | -$1.47M | -$1.70M | -$1.54M |
| Operating Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | $798557.00 | -$580079.00 | $432044.00 | $374806.00 |
| Income Before Tax | -$787624.00 | -$2.05M | -$871461.00 | -$1.17M |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Income Tax Expense | $97120.00 | $42590.00 | $36756.00 | $201500.00 |
| Net Income | -$884744.00 | -$2.09M | -$908217.00 | -$1.37M |
| Net Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS | -$0.21 | -$0.59 | -$0.28 | -$0.90 |
| Diluted EPS | -$0.21 | -$0.59 | -$0.28 | -$0.90 |
| Weighted Avg Shares Outstanding | $4.27M | $3.56M | $3.25M | $1.52M |
| Weighted Avg Shares Outstanding (Diluted) | $4.27M | $3.56M | $3.25M | $1.52M |
Financial performance has remained strong, with revenue growing from $0.00 in Q1 2024 to $0.00 in Q4 2024. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached -$1.59M in Q4 2024, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$1.18M. Net income rose to -$884744.00, keeping EPS at -$0.21. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan